Faculty
Andrew W. Lo is the Charles E. and Susan T. Harris Professor, a Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management.
His current research spans five areas: evolutionary models of investor behavior and adaptive markets, systemic risk and financial regulation, quantitative models of financial markets, financial applications of machine-learning techniques and secure multi-party computation, and healthcare finance. Recent projects include: deriving risk aversion, loss aversion, probability matching, and other behaviors as emergent properties of evolution in stochastic environments; constructing new measures of systemic risk and comparing them across time and systemic events; applying spectral analysis to investment strategies to decompose returns into fundamental frequencies; and developing new statistical tools for predicting clinical trial outcomes, incorporating patient preferences into the drug approval process, and accelerating biomedical innovation via novel financing structures.
Lo has published extensively in academic journals (see http://alo.mit.edu) and his most recent book is Adaptive Markets: Financial Evolution at the Speed of Thought. His awards include Batterymarch, Guggenheim, and Sloan Fellowships; the Paul A. Samuelson Award; the Eugene Fama Prize; the IAFE-SunGard Financial Engineer of the Year; the Global Association of Risk Professionals Risk Manager of the Year; the Harry M. Markowitz Award; the Managed Futures Pinnacle Achievement Award; one of TIME’s “100 most influential people in the world”; and awards for teaching excellence from both Wharton and MIT. His book Adaptive Markets has also received a number of awards, listed here. He is a Fellow of Academia Sinica; the American Academy of Arts and Sciences; the Econometric Society; and the Society of Financial Econometrics.
Lo is also a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory, an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science, an external faculty member of the Santa Fe Institute, and a research associate of the National Bureau of Economic Research. He is a member of the New York Federal Reserve Board’s Financial Advisory Roundtable, FINRA’s Economic Advisory Committee, the National Academy of Sciences Board on Mathematical Sciences and Their Applications, Beth Israel Deaconess Medical Center’s Board of Overseers, and the boards of Roivant Sciences and the Whitehead Institute for Biomedical Research.
Lo holds a BA in economics from Yale University and an AM and PhD in economics from Harvard University.
Chaudhuri, Shomesh E., and Andrew W. Lo. Journal of Econometrics. Forthcoming.
Lo, Andrew W., and Kien Wei Siah. Journal of Structured Finance. Forthcoming. Online Supplement. Simulation Software. Download Paper.
Lo, Andrew W. and Shomesh Chaudhuri. Forthcoming.
Hasanhodzic, Jasmina, Andrew W. Lo, and Emanuele Viola. Journal of Portfolio Management. Forthcoming. SSRN Preprint.
Vasileva, Detelina, Larry Norton, Marc Hurlbert, and Andrew W. Lo. Journal of Investment Management. Forthcoming. SSRN Preprint.
Bandi, Federico Maria, Shomesh Chaudhuri, Andrew W. Lo, and Andrea Tamoni. Journal of Financial Economics. Forthcoming. Download Paper.
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
A new study led by MIT Sloan Prof. Andrew W. Lo finds that borrowing ideas and tools from the gaming community can improve online teaching techniques and improve learning outcomes for students.
Mehr Impfstoffe, bessere Krebstherapien und neue Medikamente gegen seltene Krankheiten...der Schlüssel dazu in der Hightech-Finanzwelt liegt.
"The term Brain Capital is used to evoke the importance of valuing, investing in, and safeguarding our mental assets."
“...it’s clear that MIT is creating innovative therapeutics on a regular basis.”
“Finance plays a huge role, sometimes way too big a role, in how drugs get developed."
